Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ARTL Relative to the S&P 500

ARTL Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Artelo Biosciences Inc. (NASD:ARTL) seasonal charts above shows that a Buy Date of November 19 and a Sell Date of February 17 has resulted in a geometric average return of 17.9% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 81.57% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of ARTL, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

To download ARTL seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ARTL